- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04295629
The Effects of Ilioinguinal Nerve Block on Chronic Pain in Patients in Inguinal Hernia With Spinal Anesthesia
Research on the Effects of Ilioinguinal Nerve Block on Chronic Pain in Patients Who Undergo Inguinal Hernia With Spinal Anesthesia
Study Overview
Status
Conditions
Detailed Description
Post-operative chronic pain can be defined as the neuropathic-characterized pain persisting at least 3 months after the surgery despite healing of the operation area.
However, it is still uncertain if the underlying physio-pathologic mechanism is due to intraoperative direct nerve injury or it is resulting from indirect nerve injury caused by inflammatory mesh. Post-operative chronic pain restricts the daily activities, causes anxiety and depression, increases use of analgesics and imposes a serious economic burden by increased use of health services and medical treatment. For this reason, today post-operative chronic pain is considered as an important complication of surgery. Researchers can list the risk factors of pain development as; age, weight, preoperative and postoperative pain, surgical method, recurrence, anesthesia method. Various oral non-steroid and/or opioid agents have been used in chronic pain treatment but nowadays interest in regional anesthesia approaches is increasing due to increased systemic side effects. Aim in this study is to evaluate the effects of postoperative ilioinguinal block implementation on chronic pain in patients who will undergo inguinal hernia operation with spinal anesthesia.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bursa, Turkey
- University of Health Sciences Bursa Yuksek Ihtisas Training and Research Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ASA I-III
- Age 18-65
- Inguinal hernia operation with spinal anesthesia
- Patients who agreed to participate in the study
Exclusion Criteria:
- Mental retards and communication disorder
- Infection at the injection site
- Patient with a clotting disorder
- Local anesthetic allergy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: VAS (Visüel Analog Score)
VAS : 0-10 points 0 means: no pain 10 means: incredible pain
|
The patients underwent inguinal hernia operation randomly classified into two groups in the operating room as; Group I (n:30); spinal block (SA): All patients were given SA in sitting position and 3ml 0.5% hyperbaric bupivacaine was injected in sterile conditions with 25 G injection in L3-4, L4-5 subarachnoid space.
Times when the block reached T10 level were recorded.
Other Names:
Group 2 (n:30); SA in sitting position and 3ml 0.5% hyperbaric bupivacaine was injected in sterile conditions with 25 G injection in L3-4, L4-5 subarachnoid space and as a ilioinguinal block (IHNB) 10 ml 5% bupivacaine was injected to patients with peripheric nerve block injection in the reanimation unit after the surgery.
|
Active Comparator: LANSS (Leeds Assessment of Neuropathic Symptoms and Signs)
LANSS 0-24 points >12 points : has chronic neuropathic pain <12 points: no chronic neuropathic pain
|
The patients underwent inguinal hernia operation randomly classified into two groups in the operating room as; Group I (n:30); spinal block (SA): All patients were given SA in sitting position and 3ml 0.5% hyperbaric bupivacaine was injected in sterile conditions with 25 G injection in L3-4, L4-5 subarachnoid space.
Times when the block reached T10 level were recorded.
Other Names:
Group 2 (n:30); SA in sitting position and 3ml 0.5% hyperbaric bupivacaine was injected in sterile conditions with 25 G injection in L3-4, L4-5 subarachnoid space and as a ilioinguinal block (IHNB) 10 ml 5% bupivacaine was injected to patients with peripheric nerve block injection in the reanimation unit after the surgery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
acute pain scores( VAS)
Time Frame: 24 hours
|
Presence of pain was interrogated in the hospital within the first 24 hours (2nd, 6th, 12th, 24th hours), Visüel Analog Scale (VAS) is between 0-10 points, 0 means no pain and 10 means incredible pain.
|
24 hours
|
chronic pain scores(LANSS)
Time Frame: 6 months
|
The presence of pain that may occur in the 3rd and 6th months can be learned by contacting patients by phone.
The Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) is a neuropathic pain scale.
In LANSS follow-ups, 12 points or more were associated with neuropathic pain.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
taken amount of analgesic drugs
Time Frame: 48 hours
|
compared how many milligram analgesic agents are given to the patient will be followed.
|
48 hours
|
postoperative complications
Time Frame: 48 hours
|
compared complications such as nausea, vomiting, motor or sensorial disorder after 48 hours of operation
|
48 hours
|
hospital stay
Time Frame: 48 hours
|
compared how many days patients stayed in the hospital until they were discharged
|
48 hours
|
Collaborators and Investigators
Investigators
- Principal Investigator: Tugba Onur, MD, 2017-17/24
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017-17/24
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ilioinguinal Nerve Block
-
University of AlbertaTerminatedLocal Anesthesia | Post-operative Analgesia | Ilioinguinal Nerve BlockCanada
-
Peking University People's HospitalEnrolling by invitationCesarean Section | Quadratus Lumborum Block | Iliohypogastric/Ilioinguinal Nerve BlockChina
-
Tanta UniversityCompletedIliohypogastric and Ilioinguinal Nerve Block for Acute and Chronic Pain in Cesarean SectionEgypt
-
Lawson Health Research InstituteUnknownInferior Alveolar Nerve Block | Greater Palatine Nerve BlockCanada
-
Diskapi Teaching and Research HospitalCompletedArthroscopic Shoulder Surgery | Suprascapular Nerve Block | Axillary Nerve BlockTurkey
-
Tanta UniversityRecruitingArthroscopic Shoulder Surgery | Anterior Suprascapular Nerve Block | Interscalene Nerve BlockEgypt
-
Bozyaka Training and Research HospitalCompletedPeripheral Nerve Block | Foot and Ankle Surgery | Popliteal Nerve BlockTurkey
-
Charite University, Berlin, GermanySuspendedAnesthesia, Local | Brachial Plexus Block | Nerve BlockGermany
-
Zagazig UniversityCompletedPericapsular Nerve Group Block (PENG Block) | Lumbar Erector Spinae Plane BlockEgypt
-
Ondokuz Mayıs UniversityCompletedAnesthesia, Local | Brachial Plexus Block | Nerve BlockTurkey